TY - JOUR

T1 - Intestinal Microbiome Changes and Clinical Outcomes of Patients with Ulcerative Colitis after Fecal Microbiota Transplantation

AU - Tikunov, Artem Y.

AU - Fedorets, Valeria A.

AU - Shrainer, Evgenia V.

AU - Morozov, Vitaliy V.

AU - Bystrova, Valeria I.

AU - Tikunova, Nina V.

N1 - This study was funded by the Russian Science Foundation; Project No. 21-14-00360. Публикация для корректировки.

PY - 2023/12/15

Y1 - 2023/12/15

N2 - Background and Aims: Ulcerative colitis (UC) is a chronic inflammatory disease that affects many people. One of the possible ways to treat UC is fecal microbiota transplantation (FMT). In this study, changes in the intestinal microbiome and clinical outcomes of 20 patients with UC after FMT were estimated. Methods: FMT enemas were administrated ten times, once a day, and fecal microbiota from three donors was used for each enema. The clinical outcomes were assessed after eight weeks and then via a patient survey. The 16S rRNA profiles of the gut microbiota were compared between three samplings: samples from 20 patients with UC before and after FMT and samples from 18 healthy volunteers. Results: Clinical remission was achieved in 19 (95%) patients at week 8. Adverse events occurred in five patients, including one non-responder. A significant increase in average biodiversity was shown in samples after FMT compared to samples before FMT, as well as a decrease in the proportion of some potentially pathogenic bacteria. Conclusion: The efficacy of FMT for UC treatment was confirmed; however, the duration of remission varied substantially, possibly due to different characteristics of the initial microbiota of patients. Targeted analysis of a patient’s microbiome before FMT could increase the treatment efficacy.

AB - Background and Aims: Ulcerative colitis (UC) is a chronic inflammatory disease that affects many people. One of the possible ways to treat UC is fecal microbiota transplantation (FMT). In this study, changes in the intestinal microbiome and clinical outcomes of 20 patients with UC after FMT were estimated. Methods: FMT enemas were administrated ten times, once a day, and fecal microbiota from three donors was used for each enema. The clinical outcomes were assessed after eight weeks and then via a patient survey. The 16S rRNA profiles of the gut microbiota were compared between three samplings: samples from 20 patients with UC before and after FMT and samples from 18 healthy volunteers. Results: Clinical remission was achieved in 19 (95%) patients at week 8. Adverse events occurred in five patients, including one non-responder. A significant increase in average biodiversity was shown in samples after FMT compared to samples before FMT, as well as a decrease in the proportion of some potentially pathogenic bacteria. Conclusion: The efficacy of FMT for UC treatment was confirmed; however, the duration of remission varied substantially, possibly due to different characteristics of the initial microbiota of patients. Targeted analysis of a patient’s microbiome before FMT could increase the treatment efficacy.

KW - 16S rRNA gene sequencing

KW - clinical outcomes

KW - fecal microbiota transplantation FMT

KW - gut microbiome

KW - ulcerative colitis

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85180713547&origin=inward&txGid=5c2dd80c460607528de7e078cab9b79b

UR - https://www.mendeley.com/catalogue/cd52f3a1-2859-3681-ad8c-3ac2ef402bac/

U2 - 10.3390/jcm12247702

DO - 10.3390/jcm12247702

M3 - Article

C2 - 38137770

VL - 12

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 24

M1 - 7702

ER -